Universal Health Services (UHS) Financials

Universal Health Services (NYSE: UHS) delivered a solid start to 2026, with Q1 revenue and earnings both continuing a multi-year upward trend. However, the quarter also showed a business that remains highly leveraged, capital-intensive, and reliant on consistent cash generation to support buybacks, debt service, and dividends.

On the income statement, Q1 2026 revenue rose to $4.50 billion from $4.49 billion in Q4 2025 and $4.10 billion in Q1 2025. Net income attributable to common shareholders was $348.7 million, up modestly from $332.4 million in Q4 2025 and well above $316.7 million in Q1 2025. EPS also improved year over year, with diluted EPS at $5.65 versus $4.80 in Q1 2025, helped partly by a lower share count.

Cash generation remained strong. UHS produced $401.6 million in operating cash flow in Q1 2026, which supported $217.2 million of capital spending. That said, the company still used a substantial amount of cash on financing activities, including share repurchases and debt repayment, leaving quarter-end cash slightly lower than a year ago. The balance sheet also shows a large debt load relative to equity.

Here are the most important takeaways for investors:

• Revenue continued to grow year over year, reaching $4.50 billion in Q1 2026 versus $4.10 billion in Q1 2025.
• Bottom-line results improved, with common-share net income rising to $348.7 million from $316.7 million in Q1 2025.
• EPS increased meaningfully, as diluted EPS climbed to $5.65 from $4.80 a year ago.
• Operating cash flow was strong at $401.6 million, indicating the core business continues to convert earnings into cash.
• Gross profit remained healthy at $2.41 billion, suggesting the company continues to maintain strong spread over cost of revenue.
• Share count has trended lower versus last year, helping support EPS growth alongside operating performance.
• Capital spending remains elevated at $217.2 million in Q1 2026, which is normal for a hospital operator but keeps free cash flow under pressure.
• Balance sheet equity is dominated by noncontrolling interest, while reported common equity is still shown at zero in Q1 2026, making the structure harder for retail investors to interpret at a glance.
• Debt remains substantial, with $756.2 million of short-term debt and $3.95 billion of long-term debt on the Q1 2026 balance sheet.
• Cash was modest at just $119.0 million, which leaves the company reliant on ongoing cash generation and refinancing flexibility.

Looking at the broader four-year pattern, UHS has consistently generated strong revenue growth and recurring profits, while operating cash flow has stayed positive across nearly every quarter shown. At the same time, the company has been steadily funding buybacks and managing a meaningful debt burden. That combination can support per-share results, but it also leaves less room for error if margins soften or reimbursement pressures increase.

Overall: UHS appears to be a financially productive healthcare operator with steady earnings and cash flow, but investors should keep a close eye on leverage, capital intensity, and the sustainability of buybacks in a higher-rate environment.